Sandoz concludes acquisition of Mycamine antifungal agent from Astellas

2023-08-28
Pharmaceutical Technology
上市批准临床3期并购临床结果
Sandoz concludes acquisition of Mycamine antifungal agent from Astellas
Preview
来源: Pharmaceutical Technology
For the year ending 31 March this year, Astellas achieved sales of $105m for MycamineMycamine. Credit: BalkansCat / Shutterstock.com.
Novartis division Sandoz has concluded the acquisition of global brand rights for the antifungal agent Mycamine (micafungin sodium) from Astellas.
In January this year, Sandoz first signed an agreement to purchase the rights of MycamineMycamine from the Japanese company.
Recommended Reports
Sandoz concludes acquisition of Mycamine antifungal agent from Astellas
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Rivaroxaban in Antiphospholipid Syndrome GlobalData
Sandoz concludes acquisition of Mycamine antifungal agent from Astellas
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Rusfertide Acetate in Polycythemia Vera GlobalData
View all
Mycamine is intended for the treatment of invasive candidiasis and oesophagal candidiasis. It can also be used to prevent candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.
The antifungal agent is said to be a therapy of choice in hospitals and intensive care units across the world.
For the year ending 31 March this year, the company achieved sales of JPY14.2bn ($105m) for MycamineMycamine.
Sandoz strengthens its worldwide hospital product range and collection of anti-infective solutions through the acquisition of this key global echinocandin.
Sandoz CEO Richard Saynor said: “This is another sign of our commitment at Sandoz to driving responsible access to critical antimicrobial medicines.
“We are both investing in our production network and selectively building out our leading portfolio in this field to ensure that we can continue to offer patients around the world the right medicine at the right time.”
This month, Sandoz unveiled plans to file for regulatory approval in the US and EU for its Eylea (aflibercept) biosimilar in the next few months.
The approval for the biosimilar would be based on the randomised Phase III trial showing the non-inferiority of the biosimilar compared to Bayer and Regeneron’s Eylea in wet age-related macular degeneration (wAMD).
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。